Diagnostic, prognostic and therapeutic role of CD30 in lymphoma

Expert Review of Hematology

Volumn 10, Issue 1, 2017, Pages 29-37

  Pierce, John Matthew R ^a   Mehta, Amitkumar ^a,b  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b University of Alabama at Birmingham   (United States)

Author keywords

anaplastic large cell lymphoma; Brentuximab vedotin; CD30; cutaneous T cell lymphoma; diffuse large B cell lymphoma; Hodgkin lymphoma; peripheral T cell lymphoma

Indexed keywords

BRENTUXIMAB VEDOTIN; CD30 LIGAND; ANTIBODY CONJUGATE; ANTINEOPLASTIC AGENT; CD30 ANTIGEN;

APOPTOSIS; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CELL PROLIFERATION; CELL SURVIVAL; CLASSICAL HODGKIN LYMPHOMA; CUTANEOUS T CELL LYMPHOMA; GENE EXPRESSION; HODGKIN DISEASE; HUMAN; IMMUNE RESPONSE; IMMUNOGLOBULIN PRODUCTION; IMMUNOSCINTIGRAPHY; LARGE CELL LYMPHOMA; LYMPHOMA; NONHODGKIN LYMPHOMA; NONHUMAN; PERIPHERAL T CELL LYMPHOMA; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; ANTAGONISTS AND INHIBITORS; CHEMISTRY; CLINICAL TRIAL (TOPIC); GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MOLECULARLY TARGETED THERAPY; MORTALITY; PROGNOSIS; TREATMENT OUTCOME;

ANTIGENS, CD30; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOCONJUGATES; LYMPHOMA; MOLECULAR TARGETED THERAPY; PROGNOSIS; TREATMENT OUTCOME;

EID: 85006986117     PISSN: 17474086     EISSN: 17474094     Source Type: Journal    
DOI: 10.1080/17474086.2017.1270202     Document Type: Review

References (91)

1. de Claro RA, McGinn K, Kwitkowski V, et al. U.S. Food and Drug Administration approval summary:brentuximab vedotin for the treatment of relapsed Hodgkin lymphoma or relapsed systemic anaplastic large-cell lymphoma. Clin Cancer Res. 2012;18(21):5845–5849.
2. Moskowitz CH, Nadamanee A, Masszi T, et al. The aethera trial:results of a randomized, double-blind, placebo-controlled phase 3 study of brentuximab vedotin in the treatment of patients at risk of progression following autologous stem cell transplant for hodgkin lymphoma. Blood. 2014;124(21):673–673.
3. Schwab U, Stein H, Gerdes J, et al. Production of a monoclonal antibody specific for Hodgkin and Sternberg-Reed cells of Hodgkin’s disease and a subset of normal lymphoid cells. Nature. 1982;299(5878):65–67.
4. Stein H, Mason DY, Gerdes J, et al. The expression of the Hodgkin’s disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue:evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood. 1985;66(4):848–858.
5. Chiarle R, Podda A, Prolla G, et al. CD30 in normal and neoplastic cells. Clin Immunology. 1999;90(2):157–164.
6. Deutsch YE, Tadmor T, Podack ER, et al. CD30:an important new target in hematologic malignancies. Leuk Lymphoma. 2011;52(9):1641–1654.
7. Horie R, Watanabe T., CD30:expression and function in health and disease. Semin Immunol. 1998;10(6):457–470.
8. Muta H, Podack ER. CD30:from basic research to cancer therapy. Immunol Res. 2013;57(1–3):151–158.
9. Aizawa S, Nakano H, Ishida T, et al. Tumor necrosis factor receptor-associated factor (TRAF) 5 and TRAF2 are involved in CD30-mediated NFkappaB activation. J Biol Chem. 1997;272(4):2042–2045.
10. Gilfillan MC, Noel PJ, Podack ER, et al. Expression of the costimulatory receptor CD30 is regulated by both CD28 and cytokines. J Immunology. 1998;160(5):2180–2187.
11. Gruss HJ, Boiani N, Williams DE, et al. Pleiotropic effects of the CD30 ligand on CD30-expressing cells and lymphoma cell lines. Blood. 1994;83(8):2045–2056.
12. Kumar A, Younes A. Role of CD30 targeting in malignant lymphoma. Curr Treat Options Oncol. 2014;15(2):210–225.
13. Blazar BR, Levy RB, Mak TW, et al. CD30/CD30 ligand (CD153) interaction regulates CD4+ T cell-mediated graft-versus-host disease. J Immunology. 2004;173(5):2933–2941.
14. Dai Z, Li Q, Wang Y, et al. CD4+CD25+ regulatory T cells suppress allograft rejection mediated by memory CD8+ T cells via a CD30-dependent mechanism. J Clin Invest. 2004;113(2):310–317.
15. Falini B, Pileri S, Pizzolo G, et al. CD30 (Ki-1) molecule:a new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy. Blood. 1995;85(1):1–14.
16. Slack GW, Steidl C, Sehn LH, et al. CD30 expression in de novo diffuse large B-cell lymphoma:a population-based study from British Columbia. Br J Haematol. 2014;167(5):608–617.• Good retrospective study of CD30 expression in DLBCL.
17. Sabattini E, Pizzi M, Tabanelli V, et al. CD30 expression in peripheral T-cell lymphomas. Haematologica. 2013;e81–82. Italy.•• Retrospective study of CD30 expression in T cell lymphomas.
18. Swerdlow SH CE, Harris NL, et al. World Health Organization classification of tumours of hematopoietic and lymphoid tissues. Lyon:IARC Press; 2008.
19. Hasanali ZS, Saroya BS, Stuart A, et al. Epigenetic therapy overcomes treatment resistance in T cell prolymphocytic leukemia. Sci Transl Med. 2015;7(293):293ra102.
20. Al-Rohil RN, Torres-Cabala CA, Patel A, et al. Loss of CD30 expression after treatment with Brentuximab Vedotin in a patient with anaplastic large cell lymphoma:a novel finding. J Cutan Pathol. 2016;43:1161–1166.
21. Nielson C, Fischer R, Fraga G, et al. Loss of CD30 expression in anaplastic large cell lymphoma following Brentuximab therapy. J Drugs Dermatol. 2016;15(7):894–895.
22. Gualberto A. Brentuximab Vedotin (SGN-35), an antibody-drug conjugate for the treatment of CD30-positive malignancies. Expert Opin Investig Drugs. 2012;21(2):205–216.
23. Jacobsen ED, Sharman JP, Oki Y, et al. Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression. Blood. 2015;125(9):1394–1402.
24. Blum KA. CD30:seeing is not always believing. Blood. 2015;125(9):1358–1359.
25. Falini B, Flenghi L, Fedeli L, et al. In vivo targeting of Hodgkin and Reed-Sternberg cells of Hodgkin’s disease with monoclonal antibody Ber-H2 (CD30):immunohistological evidence. Br J Haematol. 1992;82(1):38–45.
26. Falini B, Bolognesi A, Flenghi L, et al. Response of refractory Hodgkin’s disease to monoclonal anti-CD30 immunotoxin. Lancet. 1992;339(8803):1195–1196.
27. Tazzari PL, Bolognesi A, de Totero D, et al. Ber-H2 (anti-CD30)-saporin immunotoxin:a new tool for the treatment of Hodgkin’s disease and CD30+ lymphoma:in vitro evaluation. Br J Haematol. 1992;81(2):203–211.
28. Ansell SM, Horwitz SM, Engert A, et al. Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin’s lymphoma and anaplastic large-cell lymphoma. J Clin Oncol. 2007;25(19):2764–2769.
29. Bartlett NL, Younes A, Carabasi MH, et al. A phase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignancies. Blood. 2008;111(4):1848–1854.
30. Forero-Torres A, Leonard JP, Younes A, et al. A phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma. Br J Haematol. 2009;146(2):171–179.
31. Duvic M, Reddy SA, Pinter-Brown L, et al. A phase II study of SGN-30 in cutaneous anaplastic large cell lymphoma and related lymphoproliferative disorders. Clin Cancer Res. 2009;15(19):6217–6224.
32. Blum KA, Jung SH, Johnson JL, et al. Serious pulmonary toxicity in patients with Hodgkin’s lymphoma with SGN-30, gemcitabine, vinorelbine, and liposomal doxorubicin is associated with an FcgammaRIIIa-158 V/F polymorphism. Ann Oncol. 2010;21(11):2246–2254.
33. Borchmann P, Schnell R, Fuss I, et al. Phase 1 trial of the novel bispecific molecule H22xKi-4 in patients with refractory Hodgkin lymphoma. Blood. 2002;100(9):3101–3107.
34. Hartmann F, Renner C, Jung W, et al. Treatment of refractory Hodgkin’s disease with an anti-CD16/CD30 bispecific antibody. Blood. 1997;89(6):2042–2047.
35. Schnell R, Dietlein M, Staak JO, et al. Treatment of refractory Hodgkin’s lymphoma patients with an iodine-131-labeled murine anti-CD30 monoclonal antibody. J Clin Oncol. 2005;23(21):4669–4678.
36. Francisco JA, Cerveny CG, Meyer DL, et al. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood. 2003;102(4):1458–1465.
37. Katz J, Janik JE, Younes A. Brentuximab Vedotin (SGN-35). Clin Cancer Res. 2011;17(20):6428–6436.• Good review of brentuximab vedotin.
38. Younes A, Bartlett NL, Leonard JP, et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med. 2010;363(19):1812–1821.•• Early study of brentuximab vedotin in CD30-positive lymphomas mainly HL.
39. Fanale MA, Forero-Torres A, Rosenblatt JD, et al. A phase I weekly dosing study of brentuximab vedotin in patients with relapsed/refractory CD30-positive hematologic malignancies. Clin Cancer Res. 2012;18(1):248–255.
40. Abid MB, Wang S, Loi HY, et al. ALK-negative anaplastic large cell lymphoma with CNS involvement needs more than just brentuximab vedotin. Ann Hematol. 2016;95(10):1725–1726.
41. Chen R, Palmer JM, Martin P, et al. Results of a multicenter phase ii trial of Brentuximab Vedotin as second-line therapy before autologous transplantation in relapsed/refractory Hodgkin Lymphoma. Biol Blood Marrow Transplant. 2015;21(12):2136–2140.
42. Chen R, Palmer JM, Thomas SH, et al. Brentuximab vedotin enables successful reduced-intensity allogeneic hematopoietic cell transplantation in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2012;119(26):6379–6381.
43. Duvic M, Tetzlaff MT, Gangar P, et al. Results of a phase II trial of Brentuximab Vedotin for CD30+ cutaneous T-cell lymphoma and lymphomatoid papulosis. J Clin Oncol. 2015;33(32):3759–3765.
44. Fanale MA, Horwitz SM, Forero-Torres A, et al. Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral T-cell lymphomas:results of a phase I study. J Clin Oncol. 2014;32(28):3137–3143.•• Front-line study of BV in T cell lymphomas (CD30), proof-of-concept study.
45. Federico M, Luminari S, Pellegrini C, et al. Brentuximab vedotin followed by ABVD +/- radiotherapy in patients with previously untreated Hodgkin lymphoma:final results of a pilot phase II study. Haematologica. 2016;101(4):e139–141.
46. Forero-Torres A, Holkova B, Goldschmidt J, et al. Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older. Blood. 2015;126(26):2798–2804.•• Front-line study of BV in elderly HL study.
47. Gopal AK, Ramchandren R, O’Connor OA, et al. Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation. Blood. 2012;120(3):560–568.
48. Younes A, Gopal AK, Smith SE, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma. J Clin Oncol. 2012;30(18):2183–2189.
49. Carson KR, Newsome SD, Kim EJ, et al. Progressive multifocal leukoencephalopathy associated with brentuximab vedotin therapy:a report of 5 cases from the Southern Network on Adverse Reactions (SONAR) project. Cancer. 2014;120(16):2464–2471.
50. von Geldern G, Pardo CA, Calabresi PA, et al. PML-IRIS in a patient treated with brentuximab. Neurology. 2012;79(20):2075–2077.
51. Arora A, Bhatt VR, Liewer S, et al. Brentuximab vedotin desensitization in a patient with refractory Hodgkin’s lymphoma. Eur J Haematol. 2015;95(4):361–364.
52. Story SK, Petrov AA, Geskin LJ. Successful desensitization to brentuximab vedotin after hypersensitivity reaction. J Drugs Dermatol. 2014;13(6):749–751.
53. Gandhi MD, Evens AM, Fenske TS, et al. Pancreatitis in patients treated with brentuximab vedotin:a previously unrecognized serious adverse event. Blood. 2014;123(18):2895–2897.
54. Urru SA, Mariotti E, Carta P, et al. Acute pancreatitis following brentuximab vedotin therapy for refractory Hodgkin lymphoma:a case report. Drugs R D. 2014;14(1):9–11.
55. Younes A, Connors JM, Park SI, et al. Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin’s lymphoma:a phase 1, open-label, dose-escalation study. Lancet Oncol. 2013;14(13):1348–1356.
56. Josting A, Franklin J, May M, et al. New prognostic score based on treatment outcome of patients with relapsed Hodgkin’s lymphoma registered in the database of the German Hodgkin’s lymphoma study group. J Clin Oncol. 2002;20(1):221–230.
57. Chen R, Gopal AK, Smith SE, et al. Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2016;128:1562–1566.• Long-term (5 year) data of single-agent BV in patients treated with relapse/refractory HL.
58. Chen R, Palmer JM, Tsai NC, et al. Brentuximab vedotin is associated with improved progression-free survival after allogeneic transplantation for Hodgkin lymphoma. Biol Blood Marrow Transplant. 2014;20(11):1864–1868.
59. Majhail NS, Weisdorf DJ, Defor TE, et al. Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin’s lymphoma. Biol Blood Marrow Transplant. 2006;12(10):1065–1072.
60. Sirohi B, Cunningham D, Powles R, et al. Long-term outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin’s lymphoma. Ann Oncol. 2008;19(7):1312–1319.
61. Brice P, Bouabdallah R, Moreau P, et al. Prognostic factors for survival after high-dose therapy and autologous stem cell transplantation for patients with relapsing Hodgkin’s disease:analysis of 280 patients from the French registry. Societe Francaise de Greffe de Moelle. Bone Marrow Transplant. 1997;20(1):21–26.
62. Sureda A, Constans M, Iriondo A, et al. Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin’s lymphoma autografted after a first relapse. Ann Oncol. 2005;16(4):625–633.
63. Moskowitz CH, Nademanee A, Masszi T, et al. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin’s lymphoma at risk of relapse or progression (AETHERA):a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet. 2015;385(9980):1853–1862.
64. Kumar A, Casulo C, Yahalom J, et al. Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma. Blood. 2016.
65. Boll B, Gorgen H, Fuchs M, et al. ABVD in older patients with early-stage Hodgkin lymphoma treated within the German Hodgkin Study Group HD10 and HD11 trials. J Clin Oncol. 2013;31(12):1522–1529.
66. Proctor SJ, Wilkinson J, Jones G, et al. Evaluation of treatment outcome in 175 patients with Hodgkin lymphoma aged 60 years or over:the SHIELD study. Blood. 2012;119(25):6005–6015.
67. Stamatoullas A, Brice P, Bouabdallah R, et al. Outcome of patients older than 60 years with classical Hodgkin lymphoma treated with front line ABVD chemotherapy:frequent pulmonary events suggest limiting the use of bleomycin in the elderly. Br J Haematol. 2015;170(2):179–184.
68. Hapgood G, Savage KJ. The biology and management of systemic anaplastic large cell lymphoma. Blood. 2015;126(1):17–25.
69. Jacobsen E. Anaplastic large-cell lymphoma, T-/null-cell type. Oncologist. 2006;11(7):831–840.
70. Savage KJ, Harris NL, Vose JM, et al. ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified:report from the International Peripheral T-Cell Lymphoma Project. Blood. 2008;111(12):5496–5504.
71. Pro B, Advani R, Brice P, et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma:results of a phase II study. J Clin Oncol. 2012;30(18):2190–2196.
72. Ansell SM. Brentuximab vedotin. Blood. 2014;124(22):3197–3200.• Good review of BV.
73. Ogura M, Tobinai K, Hatake K, et al. Phase I /II study of brentuximab vedotin in Japanese patients with relapsed or refractory CD30-positive Hodgkin’s lymphoma or systemic anaplastic large-cell lymphoma. Cancer Sci. 2014;105(7):840–846.
74. Karube K, Aoki R, Nomura Y, et al. Usefulness of flow cytometry for differential diagnosis of precursor and peripheral T-cell and NK-cell lymphomas:analysis of 490 cases. Pathol Int. 2008;58(2):89–97.
75. Mak V, Hamm J, Chhanabhai M, et al. Survival of patients with peripheral T-cell lymphoma after first relapse or progression:spectrum of disease and rare long-term survivors. J Clin Oncol. 2013;31(16):1970–1976.
76. International TCLP, Vose J, Armitage J, Weisenburger D. International peripheral T-cell and natural killer/T-cell lymphoma study:pathology findings and clinical outcomes. J Clin Oncol. 2008;26(25):4124–4130.
77. Weisenburger DD, Savage KJ, Harris NL, et al. Peripheral T-cell lymphoma, not otherwise specified:a report of 340 cases from the international Peripheral T-cell lymphoma project. Blood. 2011;117(12):3402–3408.
78. Horwitz SM, Advani RH, Bartlett NL, et al. Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin. Blood. 2014;123(20):3095–3100.
79. Kim YH, Tavallaee M, Sundram U, et al. Phase II investigator-initiated study of Brentuximab Vedotin in Mycosis Fungoides and Sezary syndrome with variable CD30 expression level:a multi-institution collaborative project. J Clin Oncol. 2015;33(32):3750–3758.
80. Duvic M. CD30+ neoplasms of the skin. Curr Hematol Malig Rep. 2011;6(4):245–250.
81. ALCANZA trial. 2016. Available from: https://www.takeda.com/news/2016/20160801_7498.html.
82. Campuzano-Zuluaga G, Cioffi-Lavina M, Lossos IS, et al. Frequency and extent of CD30 expression in diffuse large B-cell lymphoma and its relation to clinical and biologic factors:a retrospective study of 167 cases. Leuk Lymphoma. 2013;54(11):2405–2411.
83. Malysz J, Erdman P, Klapper J, et al. Clinical implications of CD30 expression in aggressive B-cell lymphomas. Clin Lymphoma Myeloma Leuk. 2016;16(8):429–433.
84. Bartlett NL FC, Yasenchak CA. Updated results of a phase II trial of brentuximab vedotin combined with R-CHOP in frontline treatment of patients (pts) with high-intermediate/high-risk diffuse large B-cell lymphoma (DLBCL). J Clin Oncol. 2015;(suppl; abstr 8506). Available from:http://www.onclive.com/web-exclusives/Adding-Brentuximab-Vedotin-to-Frontline-R-CHOP-Results-in-80-Response-Rate-in-Advanced-DLBCL.
85. Rylova SN, Del Pozzo L, Klingeberg C, et al. Immuno-PET imaging of CD30-positive lymphoma using 89Zr-Desferrioxamine-labeled CD30-specific AC-10 antibody. J Nucl Med:Official Pub Society Nucl Med. 2016;57(1):96–102.
86. Delacruz W, Setlik R, Hassantoufighi A, et al. Novel Brentuximab Vedotin combination therapies show promising activity in highly refractory CD30+ non-Hodgkin Lymphoma:a case series and review of the literature. Case Rep Oncol Med. 2016;2016:2596423.
87. Rael E, Rakszawski K, Koller K, et al. Treatment with rituximab and brentuximab vedotin in a patient of common variable immune deficiency-associated classic Hodgkin lymphoma. Biomarker Res. 2016;4:7.
88. Ju W, Zhang M, Wilson KM, et al. Augmented efficacy of brentuximab vedotin combined with ruxolitinib and/or Navitoclax in a murine model of human Hodgkin’s lymphoma. Proc Natl Acad Sci U S A. 2016;113(6):1624–1629.
89. Locatelli SL, Careddu G, Inghirami G, et al. The novel PI3K-delta inhibitor TGR-1202 enhances Brentuximab Vedotin-induced Hodgkin lymphoma cell death via mitotic arrest. Leukemia. 2016;30:2402–2405.
90. Wu J, Fu J, Zhang M, et al. AFM13:a first-in-class tetravalent bispecific anti-CD30/CD16A antibody for NK cell-mediated immunotherapy. J Hematol Oncol. 2015;8:96.
91. Ramos C. Chimeric T-cells for Therapy of CD30+ Hodgkin and Non-Hodgkin Lymphomas. In:ASH Annual Meeting. Orlando (FL); 2015.